Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELIVER: DYNE-251 in Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
NCT05524883Phase 2Active, not recruiting
- Sponsor
- Dyne Therapeutics
- Start
- Aug 2022
- Primary completion
- Sep 2031
- Modality
- Antisense DNA, Antibody Conjugates, Conjugated siRNA
- Countries
- 9
01
Overview
A Phase 2 trial of zeleciment rostudirsen in Duchenne muscular dystrophy (DMD), sponsored by Dyne Therapeutics. Started Aug 2022; status: active, not recruiting.
02
Drugs
zeleciment rostudirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05524883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524883.